

Statin Drugs and Risk of Advanced Prostate Cancer

Journal of the National Cancer Institute

98, 1819-1825

DOI: [10.1093/jnci/djj499](https://doi.org/10.1093/jnci/djj499)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Analysis of the National Health and Nutrition Examination Survey. Survey of Ophthalmology, 2006, 51, 525-526.	1.7	2
2	Do Statins Affect Androgen Levels in Men? Results from the Boston Area Community Health Survey. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1587-1594.	1.1	59
3	Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications. Current Pharmaceutical Design, 2007, 13, 3622-3636.	0.9	87
4	Cholesterol-Lowering Drugs and Prostate Cancer Risk: A Population-based Case-Control Study. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2226-2232.	1.1	166
5	Cholesterol-Lowering Drugs and Advanced Prostate Cancer Incidence in a Large U.S. Cohort. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2213-2217.	1.1	136
6	Epidemiologic Musing on Statin Drugs in the Prevention of Advanced Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2175-2180.	1.1	19
7	Statin Use and Risk of Prostate Cancer in the California Men's Health Study Cohort. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2218-2225.	1.1	134
8	Cholesterol Sensitivity of Endogenous and Myristoylated Akt. Cancer Research, 2007, 67, 6238-6246.	0.4	114
10	Prostate cancer prevention. Cancer, 2007, 110, 1889-1899.	2.0	60
11	Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer, 2007, 110, 2119-2152.	2.0	497
12	Cholesterol level of lipid raft microdomains regulates apoptotic cell death in prostate cancer cells through EGFR-mediated Akt and ERK signal transduction. Prostate, 2007, 67, 1061-1069.	1.2	90
13	Obesity and Prostate Cancer: A Role for Adipokines. European Urology, 2007, 52, 46-53.	0.9	137
15	Dietary fat-gene interactions in cancer. Cancer and Metastasis Reviews, 2007, 26, 535-551.	2.7	52
16	Statin use and prostate cancer risk in a large population-based setting. Cancer Causes and Control, 2008, 19, 767-774.	0.8	63
17	Hypercholesterolemia and prostate cancer: a hospital-based case-control study. Cancer Causes and Control, 2008, 19, 1259-1266.	0.8	80
18	Simvastatin inducing PC3 prostate cancer cell necrosis mediated by calcineurin and mitochondrial dysfunction. Journal of Bioenergetics and Biomembranes, 2008, 40, 307-314.	1.0	36
19	Rationale for statins in the chemoprevention of prostate cancer. Current Prostate Reports, 2008, 6, 99-106.	0.1	1
20	Rationale for statins in the chemoprevention of prostate cancer. Current Urology Reports, 2008, 9, 189-196.	1.0	23

#	ARTICLE	IF	CITATIONS
21	Pharmacokinetics, Pharmacodynamics and Drug Metabolism. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 4528-4545.	1.6	35
22	Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies. <i>International Journal of Cancer</i> , 2008, 123, 899-904.	2.3	134
23	Association between plasma cholesterol and prostate cancer in the PSA era. <i>International Journal of Cancer</i> , 2008, 123, 1693-1698.	2.3	117
24	Combination regimen with statins and NSAIDs: A promising strategy for cancer chemoprevention. <i>International Journal of Cancer</i> , 2008, 123, 983-990.	2.3	83
25	New pharmacological strategies against metastatic spread. <i>Fundamental and Clinical Pharmacology</i> , 2008, 22, 465-492.	1.0	19
26	Impact of statin therapy on survival in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2008, 111, 102-105.	0.6	72
27	Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF- κ B pathway. <i>Biochemical Pharmacology</i> , 2008, 75, 907-913.	2.0	108
28	Progress in Understanding Androgen-Independent Prostate Cancer (AIPC): A Review of Potential Endocrine-Mediated Mechanisms. <i>European Urology</i> , 2008, 53, 1129-1137.	0.9	65
29	Statins and Cancer Risk. <i>American Journal of Medicine</i> , 2008, 121, 302-309.	0.6	125
30	Consumption of dietary supplements and over-the-counter and prescription medications in men participating in the Prostate Cancer Prevention Trial at an academic center. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008, 26, 125-132.	0.8	19
31	Exploring causes for declining prostate cancer mortality rates in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008, 26, 627-633.	0.8	17
32	Do the cholesterol-lowering properties of statins affect cancer risk?. <i>Trends in Endocrinology and Metabolism</i> , 2008, 19, 113-121.	3.1	109
33	Statins in tumor suppression. <i>Cancer Letters</i> , 2008, 260, 11-19.	3.2	156
34	Statins and cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2008, 44, 2122-2132.	1.3	257
35	Statins and ATP regulate nuclear pAkt via the P2X7 purinergic receptor in epithelial cells. <i>Biochemical and Biophysical Research Communications</i> , 2008, 365, 131-136.	1.0	24
36	Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor. <i>Biochemical and Biophysical Research Communications</i> , 2008, 372, 356-361.	1.0	49
37	Caveolin-1 interacts with a lipid raft-associated population of fatty acid synthase. <i>Cell Cycle</i> , 2008, 7, 2257-2267.	1.3	80
38	Statins and prostate cancer prevention: where we are now, and future directions. <i>Nature Reviews Urology</i> , 2008, 5, 376-387.	1.4	62

#	ARTICLE	IF	CITATIONS
39	The Influence of Statin Medications on Prostate-specific Antigen Levels. Journal of the National Cancer Institute, 2008, 100, 1511-1518.	3.0	145
40	Statin Use and Risk of Prostate Cancer: Results from a Population-based Epidemiologic Study. American Journal of Epidemiology, 2008, 168, 250-260.	1.6	143
41	Chinese Red Yeast Rice Versus Lovastatin Effects on Prostate Cancer Cells With and Without Androgen Receptor Overexpression. Journal of Medicinal Food, 2008, 11, 657-666.	0.8	34
42	Prevention of Prostate Cancer: What We Know and Where We Are Going. American Journal of Men's Health, 2008, 2, 178-189.	0.7	7
43	Review of recent evidence in support of a role for statins in the prevention of prostate cancer. Current Opinion in Urology, 2008, 18, 333-339.	0.9	35
45	Prostate cancer update: 2007. Current Opinion in Oncology, 2008, 20, 294-299.	1.1	6
47	Androgens and prevention of prostate cancer. Current Opinion in Endocrinology, Diabetes and Obesity, 2008, 15, 271-277.	1.2	3
48	Cholesterol and Cholesterol-Rich Membranes in Prostate Cancer: An Update. Tumori, 2008, 94, 633-639.	0.6	60
49	Lack of Efficacy of the Statins Atorvastatin and Lovastatin in Rodent Mammary Carcinogenesis. Cancer Prevention Research, 2009, 2, 161-167.	0.7	33
50	A 64-Year-Old Man With Low-Risk Prostate Cancer. JAMA - Journal of the American Medical Association, 2009, 301, 2141.	3.8	18
51	Does statin use affect the risk of developing prostate cancer?. Nature Reviews Urology, 2009, 6, 70-71.	1.4	6
52	Prostate-Cancer Screening. New England Journal of Medicine, 2009, 361, 202-206.	13.9	15
53	Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells. Biochemical Pharmacology, 2009, 78, 1115-1126.	2.0	62
54	Pharmacological Approaches to Reducing the Risk of Prostate Cancer. European Urology, 2009, 55, 1064-1074.	0.9	25
55	Editorial Comment on: Pharmacological Approaches to Reducing the Risk of Prostate Cancer. European Urology, 2009, 55, 1073-1074.	0.9	0
56	Chemoprevention of prostate cancer: What can be recommended to patients?. Current Prostate Reports, 2009, 7, 47-53.	0.1	0
57	Chemoprevention of prostate cancer: What can be recommended to patients?. Current Urology Reports, 2009, 10, 165-171.	1.0	28
58	Effects of simvastatin, acetylsalicylic acid, and rosiglitazone on proliferation of normal and cancerous prostate epithelial Cells at therapeutic concentrations. Prostate, 2009, 69, 1017-1023.	1.2	43

#	ARTICLE	IF	CITATIONS
59	Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. <i>BMC Medical Genomics</i> , 2009, 2, 2.	0.7	421
60	Metabolic Syndrome and Prostate Cancer: A Review. <i>Clinical Oncology</i> , 2009, 21, 183-191.	0.6	27
61	Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. <i>Current Opinion in Pharmacology</i> , 2009, 9, 419-426.	1.7	64
62	No Effect of Statins on Biochemical Outcomes After Radiotherapy for Localized Prostate Cancer. <i>Urology</i> , 2009, 73, 158-162.	0.5	55
63	High cholesterol levels are associated with reduced prostate cancer mortality rates during periods of high but not low statin use in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 170-173.	0.8	14
64	Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2009, 115, 126-136.	1.2	49
65	Men with Low Serum Cholesterol Have a Lower Risk of High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2807-2813.	1.1	150
66	Ezetimibe Is an Inhibitor of Tumor Angiogenesis. <i>American Journal of Pathology</i> , 2009, 174, 1017-1026.	1.9	100
67	The Influence of Statin Medications on Prostate-specific Antigen Levels. <i>Yearbook of Urology</i> , 2009, 2009, 158-159.	0.1	0
68	ASSOCIATION BETWEEN STATINS, OBESITY AND PROSTATE TUMOR INFLAMMATORY INFILTRATE IN MEN UNDERGOING RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2009, 181, 205-205.	0.2	0
69	Risk Factors, Prevention and Early Detection of Prostate Cancer. <i>Primary Care - Clinics in Office Practice</i> , 2009, 36, 603-621.	0.7	6
70	Dietary intervention strategies to modulate prostate cancer risk and prognosis. <i>Current Opinion in Urology</i> , 2009, 19, 263-267.	0.9	25
71	Statins and Cancer: A Potential Link?. <i>American Journal of Therapeutics</i> , 2010, 17, e100-e104.	0.5	2
72	Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. <i>Cancer Causes and Control</i> , 2010, 21, 61-68.	0.8	91
73	Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001â€“2004. <i>Cancer Causes and Control</i> , 2010, 21, 671-678.	0.8	39
74	Association of serum cholesterol and cholesterol-lowering drug use with serum sex steroid hormones in men in NHANES III. <i>Cancer Causes and Control</i> , 2010, 21, 1575-1583.	0.8	20
75	A Clinical Review of Statins and Cancer: Helpful or Harmful?. <i>Pharmacotherapy</i> , 2010, 30, 177-194.	1.2	29
76	Re: Effects of Simvastatin, Acetylsalicylic Acid, and Rosiglitazone on Proliferation of Normal and Cancerous Prostate Epithelial Cells at Therapeutic Concentrations. <i>European Urology</i> , 2010, 57, 542-543.	0.9	0

#	ARTICLE	IF	CITATIONS
77	Serum low-density lipoprotein levels correlate with survival in advanced stage epithelial ovarian cancers. <i>Gynecologic Oncology</i> , 2010, 116, 78-81.	0.6	48
78	Statin medication use and the risk of biochemical recurrence after radical prostatectomy. <i>Cancer</i> , 2010, 116, 3389-3398.	2.0	112
79	Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. <i>Prostate</i> , 2010, 70, 390-400.	1.2	142
80	The impact of HMG-CoA reductase therapy on serum PSA. <i>Prostate</i> , 2010, 70, 608-615.	1.2	22
81	Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity. <i>Prostate</i> , 2010, 70, 883-888.	1.2	22
82	Statin-induced autophagy by inhibition of geranylgeranyl biosynthesis in prostate cancer PC3 cells. <i>Prostate</i> , 2010, 70, 971-981.	1.2	104
83	Statin and NSAID use and prostate cancer risk. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 752-755.	0.9	29
84	The Rafts of the Medusa: cholesterol targeting in cancer therapy. <i>Oncogene</i> , 2010, 29, 3745-3747.	2.6	19
85	Is statin use associated with prostate cancer aggressiveness?. <i>BJU International</i> , 2010, 105, 1222-1225.	1.3	36
86	Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: results from CaPSURE. <i>BJU International</i> , 2010, 106, 627-632.	1.3	38
87	Metabolomic Characterization of Human Prostate Cancer Bone Metastases Reveals Increased Levels of Cholesterol. <i>PLoS ONE</i> , 2010, 5, e14175.	1.1	135
88	Prevention Strategies in Prostate Cancer. <i>Current Oncology</i> , 2010, 17, 4-10.	0.9	10
89	Methyl- β -cyclodextrin Suppresses Hyaluronan Synthesis by Down-regulation of Hyaluronan Synthase 2 through Inhibition of Akt. <i>Journal of Biological Chemistry</i> , 2010, 285, 22901-22910.	1.6	33
90	Association between Statins and Prostate Tumor Inflammatory Infiltrate in Men Undergoing Radical Prostatectomy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 722-728.	1.1	47
91	Statin Use and the Risk of Prostate-Specific Antigen Recurrence After Radiation Therapy With or Without Hormone Therapy for Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2651-2652.	0.8	9
92	Statin Use and Risk of Prostate Cancer Recurrence in Men Treated With Radiation Therapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 2653-2659.	0.8	146
93	Atorvastatin and Celecoxib in Combination Inhibits the Progression of Androgen-Dependent LNCaP Xenograft Prostate Tumors to Androgen Independence. <i>Cancer Prevention Research</i> , 2010, 3, 114-124.	0.7	68
94	Impact of Common Medications on Serum Total Prostate-Specific Antigen Levels: Analysis of the National Health and Nutrition Examination Survey. <i>Journal of Clinical Oncology</i> , 2010, 28, 3951-3957.	0.8	115

#	ARTICLE	IF	CITATIONS
95	High-Density Lipoprotein Induces Proliferation and Migration of Human Prostate Androgen-Independent Cancer Cells by an ABCA1-Dependent Mechanism. <i>Molecular Cancer Research</i> , 2010, 8, 1284-1294.	1.5	63
96	Statin use is associated with improved prostate cancer survival: is it time for a clinical trial?. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1563-1567.	1.1	9
97	Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 19997-20002.	3.3	184
98	Statin use and cancer risk: a comprehensive review. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 603-621.	1.0	235
99	The Association Between Statin Use and the Diagnosis of Prostate Cancer in a Population Based Cohort. <i>Journal of Urology</i> , 2010, 184, 494-500.	0.2	51
100	Men Presenting for Radical Prostatectomy on Preoperative Statin Therapy Have Reduced Serum Prostate Specific Antigen. <i>Journal of Urology</i> , 2010, 183, 118-125.	0.2	42
101	2059 THE EFFECT OF DEMOGRAPHIC AND CLINICAL FACTORS ON THE RELATIONSHIP BETWEEN BMI AND PSA LEVELS. <i>Journal of Urology</i> , 2010, 183, .	0.2	0
102	Chemoprevention of Prostate Cancer. <i>Urologic Clinics of North America</i> , 2010, 37, 11-21.	0.8	16
103	Epilogue: Different approaches for prostate cancer screening in the EU?. <i>European Journal of Cancer</i> , 2010, 46, 3120-3125.	1.3	4
104	Effect of Statins on Serum Prostate-specific Antigen Levels. <i>Urology</i> , 2010, 76, 1048-1051.	0.5	17
105	Impact of HMG-CoA Reductase Inhibitor (Statin) Use on Blood Loss During Robot-Assisted and Open Radical Prostatectomy. <i>Journal of Endourology</i> , 2011, 25, 1427-1433.	1.1	2
106	Statin Clinical Trial (REALITY) for Prostate Cancer: an Over 15-Year Wait is Finally Over Thanks to a Dietary Supplement. <i>Urologic Clinics of North America</i> , 2011, 38, 325-331.	0.8	14
107	Association of Statin Use With Pathological Tumor Characteristics and Prostate Cancer Recurrence After Surgery. <i>Journal of Urology</i> , 2011, 185, 1268-1273.	0.2	46
108	The Complex Interplay Between Cholesterol and Prostate Malignancy. <i>Urologic Clinics of North America</i> , 2011, 38, 243-259.	0.8	61
109	Targeting liver X receptors in human health: deadlock or promising trail?. <i>Expert Opinion on Therapeutic Targets</i> , 2011, 15, 219-232.	1.5	73
110	The Metabolic Syndrome and Risk of Prostate Cancer in Italy. <i>Annals of Epidemiology</i> , 2011, 21, 835-841.	0.9	43
111	Cholesterol and benign prostate disease. <i>Differentiation</i> , 2011, 82, 244-252.	1.0	43
112	Statins and prostate cancer: Molecular and clinical aspects. <i>European Journal of Cancer</i> , 2011, 47, 819-830.	1.3	64

#	ARTICLE	IF	CITATIONS
113	Liver X receptors, lipids and their reproductive secrets in the male. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011, 1812, 974-981.	1.8	41
114	Re: Yang et al.: Lovastatin Causes Diminished PSA Secretion by Inhibiting AR Expression and Function in LNCaP Prostate Cancer Cells (<i>Urology</i> 2011;77:1508). <i>Urology</i> , 2011, 77, e3.	0.5	0
115	Screening for prostate cancer. <i>European Journal of Cancer</i> , 2011, 47, S164-S170.	1.3	25
116	Blood lipid levels and prostate cancer risk; a cohort study. <i>Prostate Cancer and Prostatic Diseases</i> , 2011, 14, 340-345.	2.0	51
117	Statin Use and Risk of Prostate Cancer in a Population of Men Who Underwent Biopsy. <i>Journal of Urology</i> , 2011, 186, 86-90.	0.2	39
118	Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer. <i>Research and Reports in Urology</i> , 0, Volume 3, 95-104.	0.6	0
119	Statins induce apoptosis and inhibit proliferation in cholangiocarcinoma cells. <i>International Journal of Oncology</i> , 2011, 39, 561-8.	1.4	26
120	Lovastatin Sensitizes Lung Cancer Cells to Ionizing Radiation: Modulation of Molecular Pathways of Radioresistance and Tumor Suppression. <i>Journal of Thoracic Oncology</i> , 2011, 6, 439-450.	0.5	61
121	Statins exhibit anticancer effects through modifications of the pAkt signaling pathway. <i>International Journal of Oncology</i> , 2011, 40, 867-75.	1.4	23
122	Inhibitory effect of dietary atorvastatin and celecoxib together with voluntary running wheel exercise on the progression of androgen-dependent LNCaP prostate tumors to androgen independence. <i>Experimental and Therapeutic Medicine</i> , 2011, 2, 221-228.	0.8	24
124	Effect of statin use on biochemical outcome following radical prostatectomy. <i>BJU International</i> , 2011, 108, E211-E216.	1.3	34
125	Perspective on prostate cancer screening. <i>International Journal of Clinical Practice</i> , 2011, 65, 31-34.	0.8	3
126	Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2011, 14, 63-68.	2.0	27
127	Prostate cancer gene expression signature of patients with high body mass index. <i>Prostate Cancer and Prostatic Diseases</i> , 2011, 14, 22-29.	2.0	32
128	Comparative effects of high and low-dose simvastatin on prostate epithelial cells: The role of LDL. <i>European Journal of Pharmacology</i> , 2011, 673, 96-100.	1.7	36
129	Simvastatin enhances irinotecan-induced apoptosis in human non-small cell lung cancer cells by inhibition of proteasome activity. <i>Investigational New Drugs</i> , 2011, 29, 883-890.	1.2	16
130	The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer. <i>Cancer Causes and Control</i> , 2011, 22, 417-426.	0.8	25
131	Serum total and HDL cholesterol and risk of prostate cancer. <i>Cancer Causes and Control</i> , 2011, 22, 1545-1552.	0.8	98

#	ARTICLE	IF	CITATIONS
132	The influence of cardiovascular morbidity on the prognosis in prostate cancer. Experience from a 12-year nationwide Danish population-based cohort study. <i>BMC Cancer</i> , 2011, 11, 519.	1.1	12
133	The effect of demographic and clinical factors on the relationship between BMI and PSA levels. <i>Prostate</i> , 2011, 71, 1631-1637.	1.2	28
134	Statins increase the risk of prostate cancer: A population-based case-control study. <i>Prostate</i> , 2011, 71, 1818-1824.	1.2	47
135	Improved Biochemical Outcomes With Statin Use in Patients With High-Risk Localized Prostate Cancer Treated With Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 713-718.	0.4	78
136	Minimal detection bias in the inverse association between statin drug use and advanced prostate cancer risk: A simulation study. <i>Cancer Epidemiology</i> , 2011, 35, e6-e11.	0.8	11
137	Statins and Prostate Cancer Diagnosis and Grade in a Veterans Population. <i>Journal of the National Cancer Institute</i> , 2011, 103, 885-892.	3.0	90
138	Long-term Use of Cholesterol-Lowering Drugs and Cancer Incidence in a Large United States Cohort. <i>Cancer Research</i> , 2011, 71, 1763-1771.	0.4	188
139	Chinese Red Yeast Rice Inhibition of Prostate Tumor Growth in SCID Mice. <i>Cancer Prevention Research</i> , 2011, 4, 608-615.	0.7	24
140	A Novel Two-Stage, Transdisciplinary Study Identifies Digoxin as a Possible Drug for Prostate Cancer Treatment. <i>Cancer Discovery</i> , 2011, 1, 68-77.	7.7	145
141	Atorvastatin induces autophagy in prostate cancer PC3 cells through activation of LC3 transcription. <i>Cancer Biology and Therapy</i> , 2011, 12, 691-699.	1.5	67
142	Dyslipidemia, statins and prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 981-990.	1.1	9
143	Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO Study. <i>British Journal of Cancer</i> , 2012, 107, 207-214.	2.9	52
144	Role of squalene synthase in prostate cancer risk and the biological aggressiveness of human prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2012, 15, 339-345.	2.0	25
146	Statin Use and Reduced Cancer-Related Mortality. <i>New England Journal of Medicine</i> , 2012, 367, 1792-1802.	13.9	798
147	Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths. <i>Annals of Oncology</i> , 2012, 23, 1325-1334.	0.6	90
148	Caveolin-1 and Prostate Cancer Progression. <i>Advances in Experimental Medicine and Biology</i> , 2012, 729, 95-110.	0.8	33
149	The anti-carcinogenic effect of statins in a rat model correlates with levels and synthesis of ubiquinone. <i>Biochemical and Biophysical Research Communications</i> , 2012, 425, 348-352.	1.0	9
151	Cholesterol and prostate cancer. <i>Current Opinion in Pharmacology</i> , 2012, 12, 751-759.	1.7	218

#	ARTICLE	IF	CITATIONS
152	Preoperative Statin Therapy is not Associated with Biochemical Recurrence After Radical Prostatectomy: Our Experience and Meta-Analysis. <i>Journal of Urology</i> , 2012, 188, 786-791.	0.2	27
153	Impact of Circulating Cholesterol Levels on Growth and Intratumoral Androgen Concentration of Prostate Tumors. <i>PLoS ONE</i> , 2012, 7, e30062.	1.1	108
154	Diet, Obesity, and Prostate Health: Are We Missing the Link?. <i>Journal of Andrology</i> , 2012, 33, 763-776.	2.0	38
155	Should All Patients Receive Statins to Reduce Cancer Risk After Heart Transplantation?. <i>Circulation</i> , 2012, 126, 391-391.	1.6	1
156	Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48 ^{Cre/+} LSL ^{Kras} G12D/+ mice. <i>International Journal of Cancer</i> , 2012, 131, 1951-1962.	2.3	67
157	HMG CoA reductase inhibitors, NSAIDs and risk of glioma. <i>International Journal of Cancer</i> , 2012, 131, E1031-7.	2.3	46
158	The differential effects of statins on the metastatic behaviour of prostate cancer. <i>British Journal of Cancer</i> , 2012, 106, 1689-1696.	2.9	84
159	Statin use and fatal prostate cancer. <i>Cancer</i> , 2012, 118, 4046-4052.	2.0	54
160	Genetic variants associated with predisposition to prostate cancer and potential clinical implications. <i>Journal of Internal Medicine</i> , 2012, 271, 353-365.	2.7	80
161	Selective liver X receptor modulators (SLiMs): What use in human health?. <i>Molecular and Cellular Endocrinology</i> , 2012, 351, 129-141.	1.6	102
162	Increased non-eprostate cancer death risk in clinically diagnosed prostate cancer. <i>BJU International</i> , 2012, 110, 188-194.	1.3	2
163	Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model. <i>Oncogene</i> , 2013, 32, 961-967.	2.6	117
164	The Relationship Between Nutrition and Prostate Cancer: Is More Always Better?. <i>European Urology</i> , 2013, 63, 810-820.	0.9	80
165	Atorvastatin inhibits RhoC function and limits head and neck cancer metastasis. <i>Oral Oncology</i> , 2013, 49, 778-786.	0.8	44
166	Cholesterol accumulation in prostate cancer: A classic observation from a modern perspective. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2013, 1835, 219-229.	3.3	86
167	Exercise Therapy as Treatment for Cardiovascular and Oncologic Disease After a Diagnosis of Early-Stage Cancer. <i>Seminars in Oncology</i> , 2013, 40, 218-228.	0.8	38
168	Metformin Use and All-Cause and Prostate Cancer-Specific Mortality Among Men With Diabetes. <i>Journal of Clinical Oncology</i> , 2013, 31, 3069-3075.	0.8	240
169	The Time Is Ripe for a Randomized Trial of Metformin in Clinically Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3054-3055.	0.8	15

#	ARTICLE	IF	CITATIONS
170	Re: Impact of Circulating Cholesterol Levels on Growth and Intratumoral Androgen Concentration of Prostate Tumors. <i>European Urology</i> , 2013, 63, 178-179.	0.9	1
171	Simvastatin Induces Apoptosis in Castrate Resistant Prostate Cancer Cells by Deregulating Nuclear Factor- κ B Pathway. <i>Journal of Urology</i> , 2013, 189, 1547-1552.	0.2	34
172	Simvastatin inhibits the core promoter of the TXNRD1 gene and lowers cellular TrxR activity in HepG2 cells. <i>Biochemical and Biophysical Research Communications</i> , 2013, 430, 90-94.	1.0	7
173	The Epidemiology and Molecular Mechanisms Linking Obesity, Diabetes, and Cancer. <i>Vitamins and Hormones</i> , 2013, 93, 51-98.	0.7	57
174	Statin Drugs and Prostate Cancer: Time to Consider Proactive Strategies in Patients. <i>Journal of Urology</i> , 2013, 189, 1192-1193.	0.2	1
175	Prostate Cancer and the Metabolic Syndrome. , 2013, , 107-114.		0
176	Association between Statin Usage and Prostate Cancer Prevention: A Refined Meta-Analysis Based on Literature from the Years 2005-2010. <i>Urologia Internationalis</i> , 2013, 90, 259-262.	0.6	15
177	Dysregulation of Cholesterol Homeostasis in Human Prostate Cancer through Loss of <i>ABCA1</i> . <i>Cancer Research</i> , 2013, 73, 1211-1218.	0.4	129
178	Simvastatin enhances the chemotherapeutic efficacy of S-1 against bile duct cancer. <i>Anti-Cancer Drugs</i> , 2013, 24, 1020-1029.	0.7	13
180	QSAR Model for Androgen Receptor Antagonism - Data from CHO Cell Reporter Gene Assays. <i>Journal of Steroids & Hormonal Science</i> , 2013, 01, .	0.1	2
181	A Prospective Study of Statin Drug Use and Lower Urinary Tract Symptoms in Older Men. <i>American Journal of Epidemiology</i> , 2013, 178, 797-803.	1.6	15
182	Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis. <i>Annals of Oncology</i> , 2013, 24, 1427-1434.	0.6	76
183	Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study. <i>Prostate Cancer and Prostatic Diseases</i> , 2013, 16, 254-259.	2.0	53
184	Simvastatin Inhibits Proliferation and Induces Apoptosis in Human Lung Cancer Cells. <i>Oncology Research</i> , 2013, 20, 351-357.	0.6	51
185	C282Y-HFE Gene Variant Affects Cholesterol Metabolism in Human Neuroblastoma Cells. <i>PLoS ONE</i> , 2014, 9, e88724.	1.1	5
186	Does Statin or ASA Affect Survival When Prostate Cancer Is Treated with External Beam Radiation Therapy?. <i>Prostate Cancer</i> , 2014, 2014, 1-6.	0.4	26
187	The Diet as a Cause of Human Prostate Cancer. <i>Cancer Treatment and Research</i> , 2014, 159, 51-68.	0.2	38
188	Shared common variants in prostate cancer and blood lipids. <i>International Journal of Epidemiology</i> , 2014, 43, 1205-1214.	0.9	45

#	ARTICLE	IF	CITATIONS
189	Rho-GTPases and Statins: A Potential Target and a Potential Therapeutic Tool Against Tumors?. , 2014, , 209-245.		0
190	5 α -Reductase Inhibitors and Risk of High-Grade or Lethal Prostate Cancer. JAMA Internal Medicine, 2014, 174, 1301.	2.6	38
191	Statin use and incident prostate cancer risk: does the statin brand matter? A population-based cohort study. Prostate Cancer and Prostatic Diseases, 2014, 17, 6-9.	2.0	37
192	Re: Use of Statins and the Risk of Death in Patients with Prostate Cancer. European Urology, 2014, 65, 1219-1220.	0.9	0
193	The Association between Statin Medication and Progression after Surgery for Localized Renal Cell Carcinoma. Journal of Urology, 2014, 191, 914-919.	0.2	39
194	Atypical plasma lipid profile in cancer patients: Cause or consequence?. Biochimie, 2014, 102, 9-18.	1.3	35
195	Aspirin Use is Associated with Lower Prostate Cancer Risk in Male Carriers of BRCA Mutations. Journal of Genetic Counseling, 2014, 23, 187-191.	0.9	11
196	Cholesteryl Ester Accumulation Induced by PTEN Loss and PI3K/AKT Activation Underlies Human Prostate Cancer Aggressiveness. Cell Metabolism, 2014, 19, 393-406.	7.2	671
197	Statin use and risk of prostate cancer: A Danish population-based case-control study, 1997â€“2010. Cancer Epidemiology, 2014, 38, 42-47.	0.8	45
198	The failure of cancer chemoprevention. Carcinogenesis, 2014, 35, 974-982.	1.3	64
199	Use of Statins and the Risk of Death in Patients With Prostate Cancer. Journal of Clinical Oncology, 2014, 32, 5-11.	0.8	616
200	The strategies to control prostate cancer by chemoprevention approaches. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2014, 760, 1-15.	0.4	30
201	Atorvastatin prevents ATP-driven invasiveness via P2X7 and EHBP1 signaling in PTEN-expressing prostate cancer cells. Carcinogenesis, 2014, 35, 1547-1555.	1.3	53
202	Mounting Evidence for Prediagnostic Use of Statins in Reducing Risk of Lethal Prostate Cancer. Journal of Clinical Oncology, 2014, 32, 1-2.	0.8	126
203	Arachidonic acid induction of Rho-mediated transendothelial migration in prostate cancer. British Journal of Cancer, 2014, 110, 2099-2108.	2.9	36
204	Hypercholesterolemia Induces Angiogenesis and Accelerates Growth of Breast Tumors inÂVivo. American Journal of Pathology, 2014, 184, 2099-2110.	1.9	86
205	Role of mitochondrial DNA changes in prostate cancer progression. Personalized Medicine Universe, 2014, 3, 57-58.	0.1	0
206	Re: Comparative Efficacy and Safety of Medical Treatments for the Management of Overactive Bladder: A Systematic Literature Review and Mixed Treatment Comparison. European Urology, 2014, 65, 1220-1221.	0.9	0

#	ARTICLE	IF	CITATIONS
207	Cholesterol-induced activation of TRPM7 regulates cell proliferation, migration, and viability of human prostate cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2014, 1843, 1839-1850.	1.9	74
208	Statin use and risk of prostate cancer: Results from the Southern Community Cohort Study. <i>Prostate</i> , 2015, 75, 1384-1393.	1.2	25
209	A mitochondrial DNA mutation influences the apoptotic effect of statins on prostate cancer. <i>Prostate</i> , 2015, 75, 1916-1925.	1.2	23
210	Hyper-Lipidemia and Male Fertility: A Critical Review of Literature. , 2015, 04, .		10
211	Lovastatin enhances adenovirus-mediated TRAIL induced apoptosis by depleting cholesterol of lipid rafts and affecting CAR and death receptor expression of prostate cancer cells. <i>Oncotarget</i> , 2015, 6, 3055-3070.	0.8	20
212	Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer. <i>Korean Journal of Urology</i> , 2015, 56, 630.	1.2	17
213	Prognostic impact of preoperative statin use after radical nephroureterectomy for upper urinary tract urothelial carcinoma. <i>Korean Journal of Urology</i> , 2015, 56, 498.	1.2	0
214	The effect of statins on cancer cellsâ€”review. <i>Tumor Biology</i> , 2015, 36, 4889-4904.	0.8	105
215	Statin Use Reduces Prostate Cancer All-Cause Mortality. <i>Medicine (United States)</i> , 2015, 94, e1644.	0.4	30
216	Statins are potential anticancerous agents (Review). <i>Oncology Reports</i> , 2015, 33, 1019-1039.	1.2	105
217	Statin use not associated with improved outcomes in patients treated with brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2015, 14, 179-184.	0.2	12
218	Asthma and risk of lethal prostate cancer in the Health Professionals Follow-Up Study. <i>International Journal of Cancer</i> , 2015, 137, 949-958.	2.3	17
219	The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostateâ€”specific Antigenâ€”era. <i>International Journal of Cancer</i> , 2015, 137, 2795-2802.	2.3	204
220	Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer. <i>JAMA Oncology</i> , 2015, 1, 495.	3.4	118
221	Statins are associated with a reduced risk of cholangiocarcinoma: a populationâ€”based caseâ€”control study. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 755-761.	1.1	36
222	Postdiagnostic Statin Use and the Risk of Lethal Prostate Cancer in the Health Professionals Follow-up Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1638-1640.	1.1	12
223	Statin use after radical prostatectomy reduces biochemical recurrence in men with prostate cancer. <i>Prostate</i> , 2015, 75, 211-217.	1.2	22
224	Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 21.e11-21.e17.	0.8	25

#	ARTICLE	IF	CITATIONS
225	Statin use is associated with decreased prostate cancer recurrence in men treated with brachytherapy. <i>World Journal of Urology</i> , 2015, 33, 93-97.	1.2	16
226	Lipid rafts as major platforms for signaling regulation in cancer. <i>Advances in Biological Regulation</i> , 2015, 57, 130-146.	1.4	251
227	Statin use and thyroid cancer: a population-based case-control study. <i>Clinical Endocrinology</i> , 2015, 83, 111-116.	1.2	13
228	Hypercholesterolemia Is Associated with a Shorter Time to Castration-Resistant Prostate Cancer in Patients Who Have Undergone Androgen Deprivation Therapy. <i>World Journal of Men's Health</i> , 2016, 34, 28.	1.7	7
229	Prostate Cancer: Is It a Battle Lost to Age?. <i>Geriatrics (Switzerland)</i> , 2016, 1, 27.	0.6	11
230	Simvastatin blocks TGF- β 1-induced epithelial-mesenchymal transition in human prostate cancer cells. <i>Oncology Letters</i> , 2016, 11, 3377-3383.	0.8	27
231	Statin Use and Prostate Cancer Aggressiveness: Results from the Population-Based North Carolina-Louisiana Prostate Cancer Project. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 670-677.	1.1	17
232	Racial Differences in the Association Between Preoperative Serum Cholesterol and Prostate Cancer Recurrence: Results from the SEARCH Database. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 547-554.	1.1	15
233	Cyp3a deficiency enhances androgen receptor activity and cholesterol synthesis in the mouse prostate. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 163, 121-128.	1.2	11
234	Blood lipids and prostate cancer: a Mendelian randomization analysis. <i>Cancer Medicine</i> , 2016, 5, 1125-1136.	1.3	68
235	LDL-lowering therapy and the risk of prostate cancer: a meta-analysis of 6 randomized controlled trials and 36 observational studies. <i>Scientific Reports</i> , 2016, 6, 24521.	1.6	29
236	Statin Use in Prostate Cancer: An Update. <i>Nutrition and Metabolic Insights</i> , 2016, 9, NMI.S38362.	0.8	28
237	Current and Emerging Uses of Statins in Clinical Therapeutics: A Review. <i>Lipid Insights</i> , 2016, 9, LPI.S37450.	1.0	115
238	Association between preoperative serum total cholesterol level and biochemical recurrence in prostate cancer patients who underwent radical prostatectomy. <i>Molecular and Clinical Oncology</i> , 2016, 4, 1073-1077.	0.4	11
239	Low-density lipoprotein receptors play an important role in the inhibition of prostate cancer cell proliferation by statins. <i>Prostate International</i> , 2016, 4, 56-60.	1.2	44
240	Cholesterol Metabolism and Prostate Cancer Lethality. <i>Cancer Research</i> , 2016, 76, 4785-4790.	0.4	61
241	Epithelial cell migration as a potential therapeutic target in early lung cancer. <i>European Respiratory Review</i> , 2017, 26, 160069.	3.0	16
242	Combined effects of atorvastatin and aspirin on growth and apoptosis in human prostate cancer cells. <i>Oncology Reports</i> , 2017, 37, 953-960.	1.2	30

#	ARTICLE	IF	CITATIONS
243	Statin use and risk of multiple myeloma: An analysis from the cancer research network. <i>International Journal of Cancer</i> , 2017, 141, 480-487.	2.3	18
244	Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model. <i>Prostate</i> , 2017, 77, 446-457.	1.2	20
245	Atorvastatin attenuates testosterone-induced benign prostatic hyperplasia in rats: role of peroxisome proliferator-activated receptor α 3 and cyclooxygenase α 2. <i>Fundamental and Clinical Pharmacology</i> , 2017, 31, 652-662.	1.0	11
246	27-hydroxycholesterol: A novel player in molecular carcinogenesis of breast and prostate cancer. <i>Chemistry and Physics of Lipids</i> , 2017, 207, 108-126.	1.5	41
247	The balance between induction and inhibition of mevalonate pathway regulates cancer suppression by statins: A review of molecular mechanisms. <i>Chemico-Biological Interactions</i> , 2017, 273, 273-285.	1.7	41
248	Epidemiology of Prostate Cancer. , 2017, , 107-125.		3
249	The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2017, 197, 1068-1075.	0.2	33
250	The current evidence on statin use and prostate cancer prevention: are we there yet?. <i>Nature Reviews Urology</i> , 2017, 14, 107-119.	1.9	111
251	Common medications and prostate cancer mortality: a review. <i>World Journal of Urology</i> , 2017, 35, 875-882.	1.2	15
252	Saturated fat intake and prostate cancer aggressiveness: results from the population-based North Carolina-Louisiana Prostate Cancer Project. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 48-54.	2.0	32
253	Anticancer Agents in Combination with Statins. <i>Journal of Bioequivalence & Bioavailability</i> , 2017, 09, .	0.1	7
254	Is the Evidence Sufficient to Recommend Statins for All Men With Prostate Cancer?. <i>Journal of Clinical Oncology</i> , 2017, 35, 3272-3274.	0.8	6
255	BMI and serum lipid parameters predict increasing risk and aggressive prostate cancer in Chinese people. <i>Oncotarget</i> , 2017, 8, 66051-66060.	0.8	14
256	Statin use linked with a decrease in the conversion from high-grade prostatic intraepithelial neoplasia (HGPIN) to prostate cancer. <i>Carcinogenesis</i> , 2018, 39, 819-825.	1.3	6
257	The effect of statin use on the incidence of prostate cancer: A population-based nested case-control study. <i>International Journal of Cancer</i> , 2018, 143, 190-198.	2.3	12
258	The Epidemiology of Prostate Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a030361.	2.9	461
259	Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a030569.	2.9	48
260	Low-dose statin treatment increases prostate cancer aggressiveness. <i>Oncotarget</i> , 2018, 9, 1494-1504.	0.8	15

#	ARTICLE	IF	CITATIONS
261	Hybrid nanocarrier system for guiding and augmenting simvastatin cytotoxic activity against prostate cancer. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 641-650.	1.9	19
262	Effects of statins on the chemoresistanceâ€”The antagonistic drug-drug interactions versus the anti-cancer effects. <i>Biomedicine and Pharmacotherapy</i> , 2018, 108, 1856-1865.	2.5	26
263	Longer-term Lipid-lowering Drug Use and Risk of Incident and Fatal Prostate Cancer in Black and White Men in the ARIC Study. <i>Cancer Prevention Research</i> , 2018, 11, 779-788.	0.7	19
264	New Insights in Prostate Cancer Development and Tumor Therapy: Modulation of Nuclear Receptors and the Specific Role of Liver X Receptors. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2545.	1.8	10
265	Statin Therapy to Improve Prostate Cancer Outcomes: Who, When, and for How Long?. <i>European Urology</i> , 2018, 74, 702-703.	0.9	2
266	The impact of transcription on metabolism in prostate and breast cancers. <i>Endocrine-Related Cancer</i> , 2018, 25, R435-R452.	1.6	8
267	Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of retinoblastoma protein in renal cell carcinoma. <i>Cancer Letters</i> , 2018, 431, 182-189.	3.2	16
268	Association of Statin Use With Overall and Cancer Survival. <i>JAMA Oncology</i> , 2018, 4, 1016.	3.4	1
269	The Heterogeneity of Lipid Metabolism in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1063, 33-55.	0.8	60
270	Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2018, 13, 184-200.	0.8	83
271	Diet and Cancer. , 2018, , .		0
273	Prostate Cancer Development Is Not Affected by Statin Use in Patients with Elevated PSA Levels. <i>Cancers</i> , 2019, 11, 953.	1.7	6
274	<p>>Statins induce cell apoptosis through a modulation of AKT/FOXO1 pathway in prostate cancer cells<p>>. <i>Cancer Management and Research</i> , 2019, Volume 11, 7231-7242.	0.9	28
275	Statin use, hyperlipidemia, and risk of glioma. <i>European Journal of Epidemiology</i> , 2019, 34, 997-1011.	2.5	23
276	Anti-cancer effect of doxorubicin is mediated by downregulation of HMG-Co A reductase via inhibition of EGFR/Src pathway. <i>Laboratory Investigation</i> , 2019, 99, 1157-1172.	1.7	20
277	Oxidised lowâ€density lipoprotein, a possible distinguishing lipid profile biomolecule between prostate cancer and benign prostatic hyperplasia. <i>Andrologia</i> , 2019, 51, e13321.	1.0	9
278	Cholesterol Induces Epithelial-to-Mesenchymal Transition of Prostate Cancer Cells by Suppressing Degradation of EGFR through APMAP. <i>Cancer Research</i> , 2019, 79, 3063-3075.	0.4	58
279	An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer. <i>Molecular Metabolism</i> , 2019, 25, 119-130.	3.0	55

#	ARTICLE	IF	CITATIONS
280	Mortality associated with statins in men with advanced prostate cancer treated with androgen deprivation therapy. <i>European Journal of Cancer</i> , 2019, 112, 109-117.	1.3	53
281	Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications. <i>European Journal of Cancer</i> , 2019, 112, 118-126.	1.3	36
282	Statin Use and the Risk of Prostate Cancer in Ischemic Heart Disease Patients in Taiwan. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 458-466.	2.3	10
283	Repurposed Drugs for Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 121-126.	1.0	2
284	Use of vitamin K antagonists and risk of prostate cancer: Meta-analysis and nationwide case-control study. <i>International Journal of Cancer</i> , 2019, 144, 1522-1529.	2.3	7
285	Short- and long-term association of lipid-lowering drug treatment and cardiovascular disease by estimated absolute risk in the Second Australian National Blood Pressure study. <i>Journal of Clinical Lipidology</i> , 2019, 13, 148-155.	0.6	2
286	Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1086-1093.	3.2	35
288	Statins as Anticancer Agents in the Era of Precision Medicine. <i>Clinical Cancer Research</i> , 2020, 26, 5791-5800.	3.2	103
289	A pilot window-of-opportunity study of preoperative fluvastatin in localized prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 630-637.	2.0	31
290	LDL, HDL and endocrine-related cancer: From pathogenic mechanisms to therapies. <i>Seminars in Cancer Biology</i> , 2021, 73, 134-157.	4.3	30
291	Lipid metabolism part I. , 2021, , 71-135.		0
292	Statins and Prostate Cancer: Bias, Precision Medicine, or Population Health?. <i>European Urology</i> , 2021, 79, 453-455.	0.9	1
293	Atorvastatin induces adrenal androgen downshift in men with prostate cancer: A post Hoc analysis of a pilot adaptive Randomised clinical trial. <i>EBioMedicine</i> , 2021, 68, 103432.	2.7	12
294	A Novel Ruthenium-Fluvastatin Complex Downregulates SNCG Expression to Modulate Breast Carcinoma Cell Proliferation and Apoptosis via Activating the PI3K/Akt/mTOR/VEGF/MMP9 Pathway. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-34.	1.9	4
295	Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in bone. <i>Oncogene</i> , 2021, 40, 4592-4603.	2.6	10
296	Population-wide impacts of aspirin, statins, and metformin use on prostate cancer incidence and mortality. <i>Scientific Reports</i> , 2021, 11, 16171.	1.6	6
297	Inhibition of Scavenger Receptor Class B Type 1 (SR-B1) Expression and Activity as a Potential Novel Target to Disrupt Cholesterol Availability in Castration-Resistant Prostate Cancer. <i>Pharmaceutics</i> , 2021, 13, 1509.	2.0	2
298	Tissue cholesterol metabolism and prostate cancer aggressiveness: Ethnogeographic variations. <i>Prostate</i> , 2021, 81, 1365-1373.	1.2	7

#	ARTICLE	IF	CITATIONS
299	The Heterogeneity of Lipid Metabolism in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1311, 39-56.	0.8	27
300	LDL cholesterol promotes the proliferation of prostate and pancreatic cancer cells by activating the STAT3 pathway. <i>Journal of Cellular Physiology</i> , 2021, 236, 5253-5264.	2.0	44
301	Statin Use and Risk of Prostate Cancer: A Meta-Analysis of Observational Studies. <i>PLoS ONE</i> , 2012, 7, e46691.	1.1	177
302	Inhibition of Proliferation and Induction of Autophagy by Atorvastatin in PC3 Prostate Cancer Cells Correlate with Downregulation of Bcl2 and Upregulation of miR-182 and p21. <i>PLoS ONE</i> , 2013, 8, e70442.	1.1	60
303	Influence of Statins on Survival Outcome in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate. <i>PLoS ONE</i> , 2016, 11, e0161959.	1.1	15
304	MiR-33a and statins collaboratively reduce the proliferative capacity of prostate cancer cells. <i>The European Research Journal</i> , 0, , .	0.1	1
305	Influence of serum cholesterol level and statin treatment on prostate cancer aggressiveness. <i>Oncotarget</i> , 2017, 8, 47110-47120.	0.8	24
306	Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins. <i>Oncotarget</i> , 2011, 2, 1176-1190.	0.8	77
307	The Impact of Statin Therapy on the Survival of Patients with Gastrointestinal Cancer. <i>Current Drug Targets</i> , 2019, 20, 738-747.	1.0	6
308	Clinical Potential of Statins in Prostate Cancer Radiation Therapy. , 2017, 37, 5363-5372.		19
309	Is central obesity, hyperinsulinemia and dyslipidemia associated with high-grade prostate cancer? A descriptive cross-sectional study. <i>Indian Journal of Urology</i> , 2010, 26, 502.	0.2	19
310	Serum lipid profiles: novel biomarkers predicting advanced prostate cancer in patients receiving radical prostatectomy. <i>Asian Journal of Andrology</i> , 2015, 17, 239.	0.8	14
311	Terapia z wykorzystaniem statyn a st TM ¼enie testosteronu u m TM ¼czyzn. <i>Endokrynologia Polska</i> , 2015, 65, 464-468.	0.3	3
312	Significant Association of Metabolic Indices, Lipid Profile, and Androgen Levels with Prostate Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 9841-9846.	0.5	11
313	Association Between Statin Use and Risk for Keratinocyte Carcinoma in the Veterans Affairs Topical Retinoin Chemoprevention Trial. <i>Annals of Internal Medicine</i> , 2009, 150, 9.	2.0	27
314	Lifestyle Changes, Nutritional Supplements, and General Preventive Medicine Recommendations That Can Simultaneously Improve Heart and Urologic Health: Part I. What Do I Tell Patients?. <i>Seminars in Preventive and Alternative Medicine</i> , 2007, 3, 74-87.	0.1	0
315	Statins, Diet, and Dietary Supplements for Prostate Cancer: A Potential Connection and Recommendation Based on Probability. <i>Seminars in Preventive and Alternative Medicine</i> , 2007, 3, 140-146.	0.1	0
316	Re: The influence of statins on prostate-specific antigen levels. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2009, 35, 93-94.	0.7	0

#	ARTICLE	IF	CITATIONS
318	Efectos no hipolipemiantes de las estatinas. Acta Medica Costarricense, 2008, 49, .	0.1	1
319	Obesity, Type 2 Diabetes and Cancer. , 2012, , 37-72.		1
320	The Influence of Obesity on Prostate Cancer Diagnosis and Treatment. , 0, , .		0
321	Prostate Inflammation and Prostate Cancer. , 2012, , 103-115.		2
322	Staying a Step Ahead of Cancer. , 0, , .		0
323	The Role of Cholesterol in Prostate Cancer. , 2013, , 65-83.		0
324	Prevention and Early Detection of Urologic Cancers: A Mini-Review. , 2014, S, .		0
325	Prevention of prostate cancer. Zdravstvena Zastita, 2015, 44, 49-57.	0.0	0
326	Chemoprevention of Esophageal Cancer. , 2020, , 113-125.		0
327	Long-Term Statin Use, Total Cholesterol Level, and Risk of Colorectal Cancer: A Prospective Cohort Study. American Journal of Gastroenterology, 2022, 117, 158-166.	0.2	13
328	<p>Statins Prevent Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Single-center Retrospective Study with a Median Follow-up of 51.20 Months</p>. Research and Reports in Urology, 2020, Volume 12, 439-446.	0.6	2
329	Metabolic imbalance and prostate cancer progression. International Journal of Molecular Epidemiology and Genetics, 2010, 1, 248-71.	0.4	11
330	Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins. American Journal of Cancer Research, 2011, 1, 542-61.	1.4	35
331	LXR, prostate cancer and cholesterol: the Good, the Bad and the Ugly. American Journal of Cancer Research, 2013, 3, 58-69.	1.4	10
333	Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer. Open Access Journal of Urology, 2011, 3, 95-104.	0.3	1
334	The evidence on trial: cholesterol lowering and cancer. Heart Asia, 2009, 1, 6-10.	1.1	0
335	Mechanistic Study of Inhibitory Effects of Atorvastatin and Docetaxel in Combination on Prostate Cancer. Cancer Genomics and Proteomics, 2016, 13, 151-60.	1.0	12
336	Combination of Lipitor and Celebrex inhibits prostate cancer VCaP cells in vitro and in vivo. Anticancer Research, 2014, 34, 3357-63.	0.5	10

#	ARTICLE	IF	CITATIONS
337	Atorvastatin suppresses the progression of cervical cancer via regulation of autophagy. American Journal of Translational Research (discontinued), 2020, 12, 5252-5268.	0.0	3
338	The association of statin use and biochemical recurrence after curative treatment for prostate cancer. Medicine (United States), 2022, 101, e28513.	0.4	7
339	Evidence on Statins, Omega-3, and Prostate Cancer: A Narrative Review. World Journal of Men's Health, 2022, 40, .	1.7	1
340	Cholesterol and saturated fatty acids synergistically promote the malignant progression of prostate cancer. Neoplasia, 2022, 24, 86-97.	2.3	22
341	Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer. Breast Cancer Research, 2022, 24, 12.	2.2	12
342	Antioxidant Effects of Statins by Modulating Nrf2 and Nrf2/HO-1 Signaling in Different Diseases. Journal of Clinical Medicine, 2022, 11, 1313.	1.0	40
343	5-alpha reductase inhibitors and prostate cancer mortality among men with regular access to screening and health care. Cancer Epidemiology Biomarkers and Prevention, 2022, , .	1.1	3
344	Inhibitory effect of lovastatin on human lung cancer cell proliferation by regulating the ERK1/2 and COX-2 pathways. Translational Cancer Research, 2021, 11, 0-0.	0.4	0
345	Influence of statins in metastatic castration-resistant prostate cancer patients treated with new antiandrogen therapies: a systematic review and meta-analysis. Einstein (Sao Paulo, Brazil), 2022, 20, eRW6339.	0.3	2
346	Formulation of simvastatin within high density lipoprotein enables potent tumour radiosensitisation. Journal of Controlled Release, 2022, 346, 98-109.	4.8	8
349	Atorvastatin regulates the migration and invasion of prostate cancer through the epithelial-mesenchymal transformation and matrix metalloproteinase pathways. Investigative and Clinical Urology, 2022, 63, 350.	1.0	5
350	The Association of Prediagnostic Statin Use with Aggressive Prostate Cancer from the Multiethnic Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 999-1005.	1.1	0
351	Statin Use and the Risk of Prostate Cancer Biochemical Recurrence Following Definitive Therapy: A Systematic Review and Meta-Analysis of Cohort Studies. Frontiers in Oncology, 2022, 12, .	1.3	6
352	Effects of Lovastatin on Brain Cancer Cells. Cell Transplantation, 2022, 31, 096368972211029.	1.2	6
353	Statins and prostate cancer—hype or hope? The epidemiological perspective. Prostate Cancer and Prostatic Diseases, 2022, 25, 641-649.	2.0	14
354	Statins and prostate cancer—hype or hope? The biological perspective. Prostate Cancer and Prostatic Diseases, 2022, 25, 650-656.	2.0	7
355	Effect of Metabolic Syndrome in Patients with Prostate Cancer (Review). , 0, , .		0
356	The blockage of downstream P2Y2 receptor signaling inhibits the prostate cancer cell adhesion to endothelial cells. Life Sciences, 2022, 306, 120793.	2.0	3

#	ARTICLE	IF	CITATIONS
357	Statin Use Is Associated with Better Prognosis of Patients with Prostate Cancer after Definite Therapies: A Systematic Review and Meta-Analysis of Cohort Studies. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	0.6	2
358	Long-Term Treatment with Simvastatin Leads to Reduced Migration Capacity of Prostate Cancer Cells. <i>Biomedicines</i> , 2023, 11, 29.	1.4	3
359	Association of Statin Use with the Risk of Incident Prostate Cancer: A Meta-Analysis and Systematic Review. <i>Journal of Oncology</i> , 2022, 2022, 1-13.	0.6	4
360	Targeting lipid metabolism in metastatic prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311528.	1.4	5
361	Statin therapy and sex hormones. , 2023, , 551-571.		0
364	Metabolic pathway analysis using stable isotopes in patients with cancer. <i>Nature Reviews Cancer</i> , 2023, 23, 863-878.	12.8	6